New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:41 EDTHEBHemispherx analysis of new data on protection from pulmonary damage by H5N1
Hemispherx Biopharma announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus, or H5N1, by Low Dose Natural Human IFN- Administered to the Buccal Mucosa." The global threat of an influenza pandemic emerging from avian H5N1 and H7N9 influenza viruses that are highly pathogenic for humans has mobilized a variety of efforts to mitigate the potential devastating human and economic consequences. The study demonstrated a dose-dependent sparing of the H5N1 induced pulmonary damage. Clinical studies will be required to validate similar results in humans from highly pathogenic H5N1, H7N9, or similar emerging avian influenza viruses. Thus, both H5N1 influenza virus (the subject of collaboration with the Osterhaus group) and H7N9 influenza virus (the subject of ongoing collaboration with Prof. J. Richt's group at the Center of Excellence for Emerging and Zoonotic Animal Diseases, Kansas State University are susceptible to Alferon N treatment in various model systems. The latter work was conducted at research facilities designed to enhance the capability of the US Department of Homeland Security.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
09:27 EDTHEBHemispherx says Ampligen blocks certain Ebola Viral Disease protein
Hemispherx Biopharma announced that it had received a new research report from Professor Tramontano in the Department of Life and Environmental Sciences, University of Cagliari, Italy. The biochemical study demonstrates Ampligen can successfully bind to the lethal EVD viral protein designated VP35. Experiments being conducted establish the scientific foundation for Ampligen, an experimental drug, as a potential preventive and early onset therapeutic for Ebola, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use